Nasdaq:US$13.94 (+0.46) | HKEX:HK$22.26 (+0.82) | AIM:£2.16 (+0)
搜索
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2009-02-17

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn’s Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate